暗色硼硅酸盐口服对比剂用于胃和小肠CT评估的前瞻性初步研究
多机构前瞻性初步研究纳入32例炎症性肠病或疑似腹膜癌患者,对比暗色硼硅酸盐口服对比剂与常规口服对比剂在腹盆CT中的可行性。暗色硼硅酸盐口服对比剂使肠壁与肠腔衰减差显著更高(P<.001),胃至回肠的肠壁显示、扩张及扩张肠段长度显著更高(P<.001),7例(22% [7/32];95% CI 9-40%)发现额外影像表现,未出现严重不良事件。
要点
- 暗色硼硅酸盐口服对比剂使肠壁与肠腔衰减差显著高于常规口服对比剂(P<.001)。
- 暗色硼硅酸盐口服对比剂在胃至回肠的肠壁显示、扩张及扩张肠段长度显著更高(P<.001)。
- 暗色硼硅酸盐口服对比剂未出现严重不良事件,7例(22% [7/32];95% CI 9-40%)发现额外影像表现。
核心结论
- 与常规口服对比剂相比,暗色硼硅酸盐口服对比剂改善了肠壁显示和扩张,并揭示了额外影像表现。
研究设计与样本
- 前瞻性初步多机构研究,纳入已知或疑似炎症性肠病(A中心,n=15)或疑似腹膜癌(B中心,n=17)共32例患者,先后接受常规口服对比剂标准治疗CT(阳性n=10,中性n=22)和研究性暗色硼硅酸盐口服对比剂CT,由三名放射科医生独立评估。
关键影像表现/征象
- 暗色硼硅酸盐口服对比剂使肠壁与肠腔衰减差显著高于常规口服对比剂(P<.001)。
- 暗色硼硅酸盐口服对比剂在胃至回肠的肠壁显示、扩张及扩张肠段长度显著高于常规口服对比剂(P<.001)。
- 七例(22% [7/32];95% CI 9-40%)使用暗色硼硅酸盐口服对比剂发现额外影像表现。
临床应用与阅片要点
- 暗色硼硅酸盐口服对比剂未出现严重不良事件,患者耐受性和安全性被记录。
- 每位阅片者对所有肠段均偏好暗色硼硅酸盐口服对比剂而非常规口服对比剂,但汇总结果未达统计学显著。
- 使用暗色硼硅酸盐口服对比剂发现的额外影像表现经最终共识评估是否在常规口服对比剂图像上可见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the feasibility of use of dark borosilicate oral contrast media (DBOCM) in abdominopelvic CT in comparison with conventional oral contrast media (COCM) in a multi-institutional setting.
METHODS: Patients with known or suspected inflammatory bowel disease (IBD) (Site A) or suspected peritoneal carcinomatosis (Site B), who had undergone initial standard-of-care CT using COCM (positive, n = 10; neutral n = 22), underwent research CT with DBOCM. Attenuation differences between bowel wall and lumen using COCM and DBOCM were measured. Three radiologists independently examined all examinations with COCM and DBOCM. Patient tolerance and safety were recorded. Bowel wall visualization, distention, distended bowel length, and radiologist preference for bowel visualization were rated. Imaging findings using both oral contrast media were recorded, and a final consensus evaluation was performed to evaluate whether additional findings detected with DBOCM were visible with COCM.
RESULTS: Thirty-two patients (IBD, n = 15; suspected peritoneal carcinomatosis, n = 17) were included. No severe adverse effects were seen with DBOCM. Compared to COCM, DBOCM yielded significantly higher attenuation differences between bowel wall and lumen (P < .001). Bowel wall visualization, distention, and distended bowel length was significantly higher from the stomach to the ileum using DBOCM (P < .001). DBOCM was preferred by each reader over COCM for all intestinal segments, but significance was not achieved in pooled results. Additional imaging findings were found in seven patients (22% [7/32]; 95% CI 9-40%) using DBOCM.
CONCLUSION: Compared to COCM, DBOCM yielded improved bowel wall visualization and distention, also revealing additional imaging findings.
引用
- Mileto A, Inoue A, Mohammadinejad P, et al. Prospective pilot evaluation of dark borosilicate oral contrast media for the evaluation of the stomach and small bowel using CT. Abdom Radiol (NY). 2025. PMID: 41320687. doi:10.1007/s00261-025-05308-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。